![Photo of Mamatha Mandava, M.D.](/sites/default/files/styles/sixth_1_1/public/staff-profile-images/Mamatha%20Mandava%2C%20M.D.jpeg?h=73b15fb1&itok=t8TNZVBP)
Mamatha Mandava, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 8D44C
- Bethesda, MD, 20814
- 240-858-7096
- mamatha.mandava@nih.gov
RESEARCH SUMMARY
Dr. Mandava's main research interests include hematopoietic stem cell transplantation (HSCT) for non-malignant diseases with a focus on primary immune deficiency disorders and immune regulatory disorders, improving post-transplant outcomes, and viral infections post-transplant and long-term follow-up.
Areas of Expertise
Information for Patients
Learn more about our clinical trials and the highly specialized care team that lead them.
![Photo of Mamatha Mandava, M.D.](/sites/default/files/styles/sixth_1_1/public/staff-profile-images/Mamatha%20Mandava%2C%20M.D.jpeg?h=73b15fb1&itok=t8TNZVBP)
Mamatha Mandava, M.D.
Biography
![Mamatha Mandava, M.D.](https://ccr.cancer.gov/sites/default/files/staff-profile-images/Mamatha%20Mandava%2C%20M.D.jpeg)
Mamatha Mandava, M.D.
Dr. Mandava received her medical degree from Kamineni Institute of Medical Sciences, India and trained in Pediatrics at Louisiana State University. Following residency, she worked as a hospitalist and ER physician for 3 years at LSU. She completed a Pediatric Hematology-Oncology Fellowship at the Medical University of South Carolina and did a year of Blood and Marrow transplantation fellowship at the National Institute of Health-Childrens National Medical Center. She worked in an Immunology lab on the effects of the complement system on neuroinflammation during her Pediatric Hematology/Oncology fellowship along with clinical research focusing on complications post-Hematopoietic stem cell transplant. During her BMT fellowship research, she mainly focused on transplant outcomes for sickle cell diseases, Outcomes following post-transplant viral-specific T cell therapy, immune reconstitution post-transplant, and characterization of virus-specific T cells. She joined the Immune-Deficiency Cellular Therapy Program in 2022.